Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: A report from the Swedish-Norwegian Testicular Cancer Group

Journal of Clinical Oncology

Volumn 29, Issue 15, 2011, Pages 2032-2039

  Olofsson, Sven Erik ^{a,b,c,d,e,f,g,h}   Tandstad, Torgrim ^{a,b,c,d,e,f,g,h}   Jerkeman, Mats ^{a,b,c,d,e,f,g,h}   Dahl, Olav ^{a,b,c,d,e,f,g,h}   Ståhl, Olof ^{a,b,c,d,e,f,g,h}   Klepp, Olbjørn ^{a,b,c,d,e,f,g,h}   Bremnes, Roy M ^{a,b,c,d,e,f,g,h}   Cohn Cedermark, Gabriella ^{a,b,c,d,e,f,g,h}   Langberg, Carl W ^{a,b,c,d,e,f,g,h}   Laurell, Anna ^{a,b,c,d,e,f,g,h}   Solberg, Arne ^{a,b,c,d,e,f,g,h}   Stierner, Ulrika ^{a,b,c,d,e,f,g,h}   Wahlqvist, Rolf ^{a,b,c,d,e,f,g,h}   Wijkström, Hans ^{a,b,c,d,e,f,g,h}   Anderson, Harald ^{a,b,c,d,e,f,g,h}   Cavallin Ståhl, Eva ^{a,b,c,d,e,f,g,h}  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d KAROLINSKA INSTITUTE   (Sweden)

^e TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^f UNIVERSITY OF BERGEN   (Norway)

^g UNIVERSITY OF TROMSØ   (Norway)

^h ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CARBOPLATIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; IFOSFAMIDE; LACTATE DEHYDROGENASE; MESNA; THIOTEPA; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE METASTASIS; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; DISEASE SEVERITY; DRUG MEGADOSE; FOLLOW UP; HALF LIFE TIME; HEART INFARCTION; HUMAN; KIDNEY FAILURE; LIVER CIRRHOSIS; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; OVERALL SURVIVAL; POPULATION RESEARCH; POSTOPERATIVE COMPLICATION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; SEPSIS; TREATMENT RESPONSE; VISCERAL METASTASIS;

EID: 79956308293     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.29.1278     Document Type: Article

References (29)

1. Schultz H, Sell A, Nørgaard-Pedersen B, et al: Serum alpha-fetoprotein and human chorionic gonadotropin as markers for the effect of postoperative radiation therapy and/or chemotherapy in testicular cancer. Cancer 42:2182-2186, 1978 (Pubitemid 9125873)
2. Lange PH, Vogelzang NJ, Goldman A, et al: Marker half-life analysis as a prognostic tool in testicular cancer. J Urol 128:708-711, 1982 (Pubitemid 13236336)
3. Vogelzang NJ, Lange PH, Goldman A, et al: Acute changes of alpha-fetoprotein and human chorionic gonadotropin during induction chemotherapy of germ cell tumors. Cancer Res 42:4855-4861, 1982 (Pubitemid 13206006)
4. Picozzi VJ Jr, Freiha FS, Hannigan JF Jr, et al: Prognostic significance of a decline in serum human chorionic gonadotropin levels after initial chemotherapy for advanced germ-cell carcinoma. Ann Intern Med 100:183-186, 1984 (Pubitemid 14188766)
5. Murphy BA, Motzer RJ, Mazumdar M, et al: Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Cancer 73:2520-2526, 1994 (Pubitemid 24155528)
6. Peckham MJ, McElwain TJ, Barrett A, et al: Combined management of malignant teratoma of the testis. Lancet 2:267-270, 1979 (Pubitemid 9244103)
7. Peckham MJ, Bagshaw KD, Blandy JP: Prognostic factors in advanced non-seminatous germcell testicular tumours: Results of a multicenter study - Report from the Medical Research Council Working Party on Testicular Tumours. Lancet 1:8, 1985
8. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers - International Germ Cell Cancer Collaborative Group. J Clin Oncol 15:594-603, 1997
9. Horwich A, Peckham MJ: Transient tumor marker elevation following chemotherapy for germ cell tumors of the testis. Cancer Treat Rep 70:1329-1331, 1986 (Pubitemid 17184300)
10. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989 (Pubitemid 19272848)
11. Ibrahim A, Zambon E, Bourhis JH, et al: Highdose chemotherapy with etoposide, cyclophosphamide and escalating dose of carboplatin followed by autologous bone marrow transplantation in cancer patients: A pilot study. Eur J Cancer 29A:1398-1403, 1993 (Pubitemid 23195380)
12. Rodenhuis S, Baars JW, Schornagel JH, et al: Feasibility and toxicity study of a high-dose chemotherapy regimen for autotransplantation incorporating carboplatin, cyclophosphamide and thiotepa. Ann Oncol 3:855-860, 1992 (Pubitemid 23002480)
13. WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication No. 48. Neoplasma 20:37-46, 1980
14. de Wit R, Roberts JT, Wilkinson PM, et al: Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: A randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19:1629-1640, 2001 (Pubitemid 32230862)
15. Motzer RJ, Mazumdar M, Gulati SC, et al: Phase II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Natl Cancer Inst 85:1828-1835, 1993
16. Hinton S, Catalano PJ, Einhorn LH, et al: Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: Final analysis of an intergroup trial. Cancer 97:1869-1875, 2003
17. Ehrlich Y, Brames MJ, Beck SD, et al: Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: Is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol 28:531-536, 2010
18. Germà-Lluch JR, Garcia del Muro X, Maroto P, et al: Clinical pattern and therapeutic results achieved in 1490 patients with germ-cell tumours of the testis: The experience of the Spanish Germ-Cell Cancer Group (GG). Eur Urol 42:553-562, 2002; discussion 562-563
19. van Dijk MR, Steyerberg EW, Habbema JD: Survival of non-seminomatous germ cell cancer patients according to the IGCC classification: An update based on meta-analysis. Eur J Cancer 42: 820-826, 2006
20. Sonneveld DJ, Hoekstra HJ, van der Graaf WT, et al: Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer 91:1304-1315, 2001 (Pubitemid 32267042)
21. Scholz M, Zehender M, Thalmann GN, et al: Extragonadal retroperitoneal germ cell tumor: Evidence of origin in the testis. Ann Oncol 13:121-124, 2002 (Pubitemid 34436736)
22. Hartmann JT, Nichols CR, Droz JP, et al: Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Ann Oncol 13:1017-1028, 2002
23. Culine S, Kramar A, Théodore C, et al: Randomized trial comparing bleomycin/etoposide/cisplatin with alternating cisplatin/cyclophosphamide/ doxorubicin and vinblastine/bleomycin regimens of chemotherapy for patients with intermediate- and poor-risk metastatic nonseminomatous germ cell tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. J Clin Oncol 26:421-427, 2008 (Pubitemid 351171694)
24. Fosså SD, Paluchowska B, Horwich A, et al: Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948). Br J Cancer 93:1209-1214, 2005 (Pubitemid 41679405)
25. Droz JP, Kramar A, Biron P, et al: Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: Mature results of a randomised trial. Eur Urol 51:739-746, 2007; discussion 747-748
26. Motzer RJ, Nichols CJ, Margolin KA, et al: Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors. J Clin Oncol 25:247-256, 2007 (Pubitemid 350003012)
27. van Dijk MR, Steyerberg EW, Stenning SP, et al: Identifying subgroups among poor prognosis patients with nonseminomatous germ cell cancer by tree modelling: A validation study. Ann Oncol 15: 1400-1405, 2004 (Pubitemid 39295028)
28. Fizazi K, Culine S, Kramar A, et al: Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 22:3868-3876, 2004 (Pubitemid 41079867)
29. Nichols CR, Kollmannsberger C: Vox populi: Using community-based studies to determine best management of early-stage nonseminoma. J Clin Oncol 27:2114-2116, 2009